Monitor for Phase 2/3 clinical data updates and any partnership or financing announcements.
Price Chart
Executive Summary
Silexion Therapeutics reported new preclinical data for SIL204, demonstrating statistically significant upregulation of FAS (death receptor) and downregulation of HLA-G (immune checkpoint) in KRAS-mutant pancreatic and NSCLC cell lines. These findings build on prior MHC-I data and support a multi-mechanism immune-sensitization profile, but remain preclinical with no financial data or clinical results in the filing.
Key Facts
- SIL204 treatment produced statistically significant, dose-dependent increases in FAS expression (up to ~2-fold, P<0.0001) in KRAS G12D pancreatic cancer cells.
- SIL204 produced statistically significant reductions in HLA-G expression in KRAS G12C NSCLC cells (P<0.001 at 24h, P<0.01 at 72h).
- Findings observed across four KRAS mutations (G12D, G12V, G12C, G12R) in pancreatic and NSCLC cell lines.
- Company initiated its first clinical trial site at Tel Aviv Sourasky Medical Center at end of July 2026 for Phase 2/3 evaluation of SIL204.
- No financial data, revenue, earnings, or guidance were provided in this filing.
Financial Impact
No financial figures reported; preclinical data only.
Risk Factors
- Preclinical findings may not translate to clinical outcomes.
- Company has a going concern risk given $2M market cap and no disclosed revenue.
- Nasdaq listing risk is flagged in forward-looking statements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-003796 |
| Exhibit: exhibit_99-1.htm | 0001178913-26-003796 |
| Document: 0001178913-26-003796-index-headers.html | 0001178913-26-003796 |
| Document: 0001178913-26-003796-index.html | 0001178913-26-003796 |
| Document: 0001178913-26-003796.txt | 0001178913-26-003796 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1890 (−22.89%) |
Oct 5, 2026 21d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1890 (+28.08%) |
Sep 30, 2026 26d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1890 (−31.77%) |
Sep 30, 2026 26d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1890 (+31.84%) |
Sep 29, 2026 27d ago | 8-K | $0.3180 | awaiting T+20 | — | $0.1890 (+40.57%) |
Sep 29, 2026 27d ago | Press Release | $0.3184 | awaiting T+20 | — | $0.1890 (+40.64%) |
Sep 28, 2026 28d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1890 (−23.91%) |
Sep 28, 2026 28d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1890 (−23.91%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1890 (+23.91%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1890 (+55.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers